Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

gulate activation of NF-kB by binding to IKKB, the kinase that inhibits NF-kB activation. The triterpenoids block the activation of STAT3 and STAT5 in cancer cells by upregulating negative regulators of the STATs. These transcription factors are the target of major drug development programs at multiple companies with applications in treating both inflammation and cancer.

-- A description of the anti-inflammatory and anti-carcinogenic activity of the compounds. Reata's triterpenoids suppress production of pro-inflammatory cytokines and reduce mortality in animal models of LPS-induced inflammation. Synthetic triterpenoids are highly effective in preventing the development of both lung cancer and liver cancer in animals exposed to known carcinogens.

-- Multi-functional anti-cancer activity of these drugs, which includes driving immature cancerous cells to differentiate; inhibiting the growth of cancer cells and causing them to undergo programmed cell death (called apoptosis). This activity has been seen in multiple animal models, and has recently been confirmed in a Phase 1 study of RTA 402 in cancer patients being conducted at the M.D. Anderson Cancer Center and the Dana-Farber Cancer Institute.

-- A comparison of the mechanism of the Synthetic Triterpenoids with that of "targeted therapies" currently in vogue in the cancer field. Dr. Sporn argues that the genetic complexity of cancer requires the use of agents with a multi-factorial mode of action, rather than those with high affinity for a single, specific molecular receptor. While multi-factorial mechanisms are often thought to be associated with high drug toxicity, Dr. Sporn notes that these agents are derived from natural products that have been safely used for centuries with no appreciable toxicities. Recent clinical studies have shown that these agents are minimally toxic in humans.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
(Date:9/19/2014)... Sept. 19, 2014  CytRx Corporation (Nasdaq: ... in oncology, today announced that David J. Haen ... 2014 NewsMakers in the Biotech Industry Conference on Friday, September ... conference will take place at the Millennium Broadway Hotel ... A live and archived webcast of the presentation ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... U.S. Food and Drug Administration is warning the public ... law enforcement personnel as part of a continued international ... The criminals call the victims -- who ... or via "telepharmacies" -- and identify themselves as FDA ...
... EDDA Technology, a leading provider of advanced computer ... successful commercial installation of its IQQA®-Liver Enterprise product ... one of the top performing living donor liver ... use EDDA Technology,s IQQA®-Liver Enterprise in conjunction with ...
Cached Medicine Technology:FDA Warns Public of Continued Extortion Scam By FDA Impersonators 2FDA Warns Public of Continued Extortion Scam By FDA Impersonators 3EDDA Technology Successfully Installs IQQA®-Liver at Mayo Clinic in Arizona 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... by stress and family conflicts before surgery may face ... new study suggests. Investigators found that patients with ... three times greater risk for complications compared to those ... "We,ve long known that patient quality of life is ...
(Date:9/19/2014)... 2014 MetroMD, a leading anti-ageing clinic has ... of human health. This therapy has grown tremendously across USA ... more effective, safe and dependable. It has far reaching benefits ... to live a very healthy and active lifestyle even beyond ... therapy, a senior therapist at MetroMD said, “HGH or Human ...
(Date:9/19/2014)... 19, 2014 In partnership with Raw Beauty ... active part of the project’s social media efforts. StudioPMG is ... to re-define the perception of beauty as it applies to ... an idea by Shelly Baer and Vanessa Silberman, who wanted ... sexy and beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2
... (MRSA) and other pesky bacteria. Andrei Osterman ... identify new targets for antibiotics and produced first-generation chemical ... (nicotinate mononucleotide adenylyltransferases). Described in a recent article in ... led by Dr. Osterman, has provided proof of concept ...
... that may explain why the disease hasn,t posed more problems, study ... virus that,s sweeping across the United States isn,t a total stranger ... that should ease the most drastic worries about the lethality of ... press is that the swine flu is totally new, so there ...
... WYCKOFF, N.J., Nov. 16 HealthBarn USA®, ... for children and families, presented at the national Farm-Based ... in Tarrytown, NY held November 12-14, 2009. HealthBarn ... because of its focus on food and nutrition and ...
... , ATLANTA, Nov. 16 AutoTrader.com will use the power ... visitors, to help raise funds for St. Jude Children,s Research ... display ads throughout the site illustrating the research and treatment ... Also, individuals who purchase an advertisement to sell a vehicle ...
... Ga. A powerful new breast cancer treatment could ... inhibits cancer,s hallmark wild growth with another that blocks ... eats part of itself, researchers say. While they ... drugs called histone deacetylase inhibitors, or HDAC inhibitors, also ...
... Va. (Nov. 16, 2009) Virginia Commonwealth University Medical ... and survival rates dramatically for cardiac arrest patients by ... body temperature in the field during resuscitation and following ... strategies to improve the odds of survival. The ...
Cached Medicine News:Health News:The Burnham buzz 2Health News:The Burnham buzz 3Health News:The Burnham buzz 4Health News:Immunity to Swine Flu May Be Broader Than Thought 2Health News:Immunity to Swine Flu May Be Broader Than Thought 3Health News:Youth Nutrition Education Needed In Farm-Based Education Programs To Combat Childhood Obesity 2Health News:AutoTrader.com to Raise Money for St. Jude Children's Research Hospital(R) 2Health News:AutoTrader.com to Raise Money for St. Jude Children's Research Hospital(R) 3Health News:New combination therapy could deliver powerful punch to breast cancer 2Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 2Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 3Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 4Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 5
... warfarin for use by healthcare professionals and ... easy-to-read back-lit display and an operator rechargeable ... the ability to auto-send results to a ... LIS or EMR database through a clinical ...
... The NOW RSV test is the easiest ... are available in 15 minutes with no hands-on ... parents prior to the child leaving the pediatrician's ... hospital admission to help control outbreaks. Now the ...
The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
... The Instacup Multi-Drug Screen Panel is used for the ... urine. The Instacup Panel consists of a test cup ... test card is inserted and the sample sealed with ... is not necessary to remove the test card to ...
Medicine Products: